pd 98059 has been researched along with Leucocythaemia in 11 studies
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, in this study, we show for the first time that PD could protect the leukemia cells independent of ERK pathway inhibition, besides, we also report a detailed mechanism for antiapoptotic effect of LY in HL-60 cells against the cytotoxicity induced by a boswellic acid analog BA145." | 3.79 | Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059. ( Andotra, SS; Bhat, WW; Bhushan, S; Guru, SK; Joshi, A; Kumar, A; Kumar, S; Malik, FA; Pathania, AS; Saxena, AK; Shah, BA; Sharma, PR; Singh, J; Taneja, SC, 2013) |
| "Four cell lines and all chronic lymphocytic leukemia cells were killed in 6 hours by vinblastine alone." | 1.36 | Vinblastine induces acute, cell cycle phase-independent apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when Mcl-1 is suppressed. ( Albershardt, TC; Bates, DJ; Eastman, A; Lowrey, CH; Salerni, BL, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (72.73) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pathania, AS | 1 |
| Joshi, A | 1 |
| Kumar, S | 1 |
| Guru, SK | 1 |
| Bhushan, S | 1 |
| Sharma, PR | 1 |
| Bhat, WW | 1 |
| Saxena, AK | 1 |
| Singh, J | 1 |
| Shah, BA | 1 |
| Andotra, SS | 1 |
| Taneja, SC | 1 |
| Malik, FA | 1 |
| Kumar, A | 1 |
| Song, H | 1 |
| Kim, KE | 1 |
| Hur, D | 1 |
| Lim, JS | 1 |
| Yang, Y | 1 |
| Cho, BJ | 1 |
| Kim, CH | 1 |
| Kim, T | 1 |
| Bang, S | 1 |
| Lee, WJ | 1 |
| Park, H | 1 |
| Cho, D | 1 |
| Salerni, BL | 1 |
| Bates, DJ | 1 |
| Albershardt, TC | 1 |
| Lowrey, CH | 1 |
| Eastman, A | 1 |
| Gao, N | 1 |
| Budhraja, A | 1 |
| Cheng, S | 1 |
| Liu, EH | 1 |
| Huang, C | 1 |
| Chen, J | 1 |
| Yang, Z | 1 |
| Chen, D | 1 |
| Zhang, Z | 1 |
| Shi, X | 1 |
| Mas, VM | 1 |
| Hernandez, H | 1 |
| Plo, I | 1 |
| Bezombes, C | 1 |
| Maestre, N | 1 |
| Quillet-Mary, A | 1 |
| Filomenko, R | 1 |
| Demur, C | 1 |
| Jaffrézou, JP | 1 |
| Laurent, G | 1 |
| Minami, Y | 1 |
| Yamamoto, K | 1 |
| Kiyoi, H | 1 |
| Ueda, R | 1 |
| Saito, H | 1 |
| Naoe, T | 1 |
| Li, DJ | 1 |
| Zhang, YZ | 1 |
| Huang, W | 1 |
| Meng, FK | 1 |
| Hazlehurst, LA | 1 |
| Argilagos, RF | 1 |
| Dalton, WS | 1 |
| Gocek, E | 1 |
| Kiełbiński, M | 1 |
| Marcinkowska, E | 1 |
| Champelovier, P | 1 |
| El Atifi, M | 1 |
| Pautre, V | 1 |
| Rostaing, B | 1 |
| Berger, F | 1 |
| Seigneurin, D | 1 |
| Dai, Y | 1 |
| Yu, C | 1 |
| Singh, V | 1 |
| Tang, L | 1 |
| Wang, Z | 1 |
| McInistry, R | 1 |
| Dent, P | 1 |
| Grant, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Vinblastine Versus Oral Hydroxiurea in Newly Diagnosed AML With Hyperleukocytosis: a Phase 2 Clinical Study[NCT05062278] | Phase 2 | 46 participants (Anticipated) | Interventional | 2021-07-26 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 other studies available for pd 98059 and Leucocythaemia
| Article | Year |
|---|---|
Reversal of boswellic acid analog BA145 induced caspase dependent apoptosis by PI3K inhibitor LY294002 and MEK inhibitor PD98059.
Topics: Apoptosis; Chromones; Flavonoids; HL-60 Cells; Humans; Leukemia; MAP Kinase Signaling System; Morpho | 2013 |
IL-18 enhances ULBP2 expression through the MAPK pathway in leukemia cells.
Topics: Anthracenes; Cell Line, Tumor; Cytotoxicity, Immunologic; Flavonoids; Gene Expression Regulation, Ne | 2008 |
Vinblastine induces acute, cell cycle phase-independent apoptosis in some leukemias and lymphomas and can induce acute apoptosis in others when Mcl-1 is suppressed.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cycloheximide; Cytoprotection; Drug Screening Assays, Antit | 2010 |
Interruption of the MEK/ERK signaling cascade promotes dihydroartemisinin-induced apoptosis in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Artemisinins; Caspases; Cytochromes c; Extracellular Sign | 2011 |
Protein kinase Czeta mediated Raf-1/extracellular-regulated kinase activation by daunorubicin.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Acetylcysteine; Androstadienes; Antibiotics, Antineoplastic; | 2003 |
Different antiapoptotic pathways between wild-type and mutated FLT3: insights into therapeutic targets in leukemia.
Topics: Apoptosis; bcl-X Protein; Cell Division; Cell Line; Chromones; Dose-Response Relationship, Drug; Dow | 2003 |
[To inhibit ERK for enhancing chemotherapy sensitivity of drug-resistance cell lines of leukemia and ovarian carcinoma].
Topics: Apoptosis; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Flavonoids; HL-60 Cells; Humans; Le | 2003 |
Beta1 integrin mediated adhesion increases Bim protein degradation and contributes to drug resistance in leukaemia cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; | 2007 |
Activation of intracellular signaling pathways is necessary for an increase in VDR expression and its nuclear translocation.
Topics: Active Transport, Cell Nucleus; Calcitriol; Cell Nucleus; Cells, Cultured; Chromones; Enzyme Inhibit | 2007 |
Specific inhibition of basal mitogen-activated protein kinases and phosphatidylinositol 3 kinase activities in leukemia cells: a possible therapeutic role for the kinase inhibitors.
Topics: Anthracenes; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Differentiation; Cell Division; Cell L | 2008 |
Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells.
Topics: Alkaloids; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Butadienes; Caspas | 2001 |